Gout Market Size, Epidemiology, Treatment, Therapies, Pipeline and…

Gout Market Size, Epidemiology, Treatment, Therapies, Pipeline and…


Gout Market Size, Epidemiology, Treatment, Therapies, Pipeline and Competitive Analysis by DelveInsight|  Companies - Selecta Biosciences, Arthrosi Therapeutics, AstraZeneca, Fuji Yakuhin

Gout is a common form of inflammatory arthritis. It’s due to a crystal called uric acid. Gout causes pain and swelling in one or more joints. It typically affects the big toe. But it also occurs in other joints, including the knee, ankle, foot, hand, wrist, and elbow. It is more common in men than women. Gout usually develops in middle age.

DelveInsights “Gout Market Insights, Epidemiology and Market Forecast – 2032” The report provides an in-depth understanding of gout, historical and projected epidemiology, and gout market trends in United States, EU5 (Germany, Spain, Italy, France and UK) and Japan.

To know more about Gout Market Report, Click Here : Evaluation of the gout market

Some facts about the gout market are:

  • In a study based on the US National Health and Nutrition Examination Survey [NHANES] (nd), conducted in 2007-2008, 3.9% of the US population reported physician-diagnosed prevalent gout. The male to female ratio was 3:1.
  • Roddy et al. (2020) cited that the prevalence of gout varies widely depending on the population studied and the methods used, but ranges from a prevalence of < 1% to 6.8%.
  • In the United Kingdom, the prevalence of gout in 2012 was 2.49% (95% CI, 2.48-2.51%) according to Clinical Practice Research Data Link (CPRD) (2012).
  • The prevalence of gout is higher in men than in women. Men can be three times more likely to be affected than women because they have higher levels of uric acid for most of their lives. Women reach these uric acid levels after menopause.
  • According to the study by Bonnemaire et al. (2008) reported the prevalence of gout in Germany as 1.4% in the general population in 2000–2005, which was the same as in the UK during that period, determined using the same case definition and data source. In comparison, France and Italy have a lower prevalence of gout.
  • SEL-212, AR882 and other emerging therapies are delivering positive top-line results in their clinical trials. These emerging…


Source story

More to explorer